Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06768827 · ClinicalTrials.gov registry record · NA
New Mechanisms of Obesity
A NA study of Insulin Resistance and Obesity and Overweight, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT06768827: Recruiting NA study of Insulin Resistance and Obesity and Overweight, sponsored by Yale University.
NCT06768827 is a NA study of Insulin Resistance and Obesity and Overweight that is actively recruiting participants, run by Yale University. The registered enrollment target is 55 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06768827, a NA study of Insulin Resistance and Obesity and Overweight, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.
Primary Outcome
Changes in adipose tissue lipolysis occurring after colonic fermentation (stimulated by lactulose) will be compared between youth with obesity and insulin resistance (OIR) and with obesity and without insulin resistance (OIS). Lipolysis will be measured by using change in D5-glycerol concentration.
Conditions Studied
Interventions
- OTHER Lactulose Oral Product
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2030-03-31 |
| Phase | NA |
What NCT06768827 shows while recruiting
NCT06768827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Lactulose Oral Product is the first listed.
NCT06768827 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06768827 about?
NCT06768827 is a clinical study titled "New Mechanisms of Obesity". Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in yo...
What is the current status of trial NCT06768827?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2025-11-13. Estimated completion is 2030-03-31.
What conditions does trial NCT06768827 study?
This clinical trial studies the following conditions: Insulin Resistance, Obesity and Overweight, Obesity and Obesity-related Medical Conditions.
What interventions are being tested in trial NCT06768827?
The interventions under investigation include: Lactulose Oral Product (OTHER).
Who is sponsoring clinical trial NCT06768827?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06768827 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06768827's enrollment target sits among peer trials
55 58th of 120 higher than 62 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
Neuromuscular Electrical Stimulation: A Novel Treatment for Improving Metabolism
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI